Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC).
Jimmy L ZhaoEmmanuel S AntonarakisHeather H ChengDaniel J GeorgeRahul R AggarwalElyn RiedelTakayuki SumiyoshiJoseph D SchonhoftAmanda AndersonNinghui MaoSamuel HaywoodBrooke DeckerTracy CurleyWassim AbidaFelix Y FengKaren KnudsenBrett CarverMario E LacoutureAlexander W WyattDana E RathkopfPublished in: British journal of cancer (2023)
ClinicalTrials.gov identifier: NCT02833883.